|
|
On Friday, The FDA Approved Vanda Pharmaceuticals' Bysanti (Milsaperidone) Tablets, A First Line Therapy For The Acute Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder And For Schizophrenia In Adults
|
|
|
|
Trading Halt: Halt status updated at 6:15:00 PM ET: Quotation Resumption: News and Resumption Times
|
|
|
|
Vanda Pharmaceuticals Obtains FDA Approval For BYSANTI For The Treatment Of Bipolar I Disorder And Schizophrenia; BYSANTI Expected To Be Commercially Available In Q3 2026
|
|
|
|
Trading Halt: Halted at 4:17:16 p.m. ET - Trading Halt: Halt News Pending
|
|
|
|
Vanda Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY26 sales guidance below estimates.
|
|
|
|
Rollins Posts Downbeat Results, Joins Paycom Software, Cisco, Applovin And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
|
|
|
|
Vanda Pharmaceuticals Files Prospectus For Offering Mixed Shelf; Terms Not Disclosed
|
|
|
|
12 Health Care Stocks Moving In Wednesday's After-Market Session
|
|
|
|
Vanda Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY26 sales guidance below estimates.
|
|
|
|
Vanda Pharmaceuticals Sees FY2026 Sales $230.000M-$260.000M vs $271.275M Est
|
|